Program
diroximel fumarate
Also written as “Diroximel fumarate”, “ALKS 8700” and “Diroximel Fumarate”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting, led by Biogen.
Furthest: phase 3, since Dec 16, 20155 company-led studies, 1 open or runningNext primary completion: Jul 28, 2034 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 51 open or running | phase 3since Dec 16, 2015 | Dec 16, 2015 | Jul 28, 2034phase 3 · NCT07483632 |
Also a collaborator on its studies: Alkermes.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2015First study: phase 3 study in Multiple SclerosisFirst studyNCT02634307 · 1,057 enrolled · United States, Belgium, Bulgaria and more
- Mar 16, 2017Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT03093324 · 506 enrolled · United States, Germany, Poland
- Oct 6, 2021Phase 3 study in Relapsing Forms of Multiple SclerosisNCT05083923 · 136 enrolled · China, Japan
- Nov 9, 2021Phase 1 study in Healthy VolunteersNCT05127564 · 32 enrolled · Hong Kong, New Zealand
- Feb 26, 2026Phase 3 study in Relapsing Forms of Multiple SclerosisNCT07483632 · 185 planned
Ahead
- Jul 28, 2034Primary completion: phase 3 study in Relapsing Forms of Multiple SclerosisNCT07483632
TargetBeta
KEAP1 →read by rule
“Kelch-like ECH-associated protein 1 inhibitor”ChEMBL 37, by rule
Other programs on KEAP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dimethyl Fumaraterule | Biogen | phase 4 | 37 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07483632Relapsing Forms of Multiple Sclerosis | 3 | Not yet recruiting | Jul 28, 2034 | 185 |
| NCT05127564Healthy Volunteers · Hong Kong, New Zealand | 1 | Completed | Jun 9, 2022 | 32 |
| NCT05083923Relapsing Forms of Multiple Sclerosis · China, Japan | 3 | Completed | Sep 11, 2024 | 136 |
| NCT03093324Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Poland | 3 | Completed | Jun 27, 2019 | 506 |
| NCT02634307Multiple Sclerosis · United States, Belgium, Bulgaria and more | 3 | Completed | Jun 1, 2021 | 1,057 |
How it is read
Names in the registry
- “Diroximel fumarate”, 2 entries
- “ALKS 8700”, 2 entries
- “Diroximel Fumarate”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 2 studies
- Multiple Sclerosis, Relapsing-Remitting, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.